Study of Epratuzumab (hLL2) in Patients With Waldenstrom's Macroglobulinemia
NCT00113802
·
clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
31
Enrollment
INDUSTRY
Sponsor class
Stopped
low accrual
Conditions
Waldenstrom Macroglobulinemia
Interventions
DRUG:
Epratuzumab (hLL2- anti-CD22 humanized antibody)
Sponsor
Gilead Sciences